The Advisory Council on the Misuse of Drugs (ACMD) has recommended ketamine retain its Class B classification, emphasizing the need for improved support to address related harms. The decision follows a review of evidence, stakeholder consultations, and analysis of emerging risks. ACMD noted acute harms, such as toxicity and deaths, align with its current classification. However, the council highlighted concerns about high-dose use and long-term risks, stressing that reclassification alone would not mitigate these issues. Recommendations include strengthening identification, prevention, and response efforts by police and healthcare professionals, alongside a coordinated public health approach. The ACMD stressed that addressing ketamine-related harms requires collaboration across public bodies, health services, and community organizations. The report underscores the importance of targeted interventions over reclassification to reduce harm effectively.
© Crown copyright, 2024, GOV.UK.
Summary adapted from content licensed under the Open Government Licence v3.0.
For details, see https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/.
Original source: https://www.gov.uk/
https://www.gov.uk/government/news/acmd-announces-decision-on-the-classification-of-ketamine
Made by AI. If you spot anything of concern write us at contact@cybach.com. We’ll promptly correct irregularities.